Literature DB >> 17502243

Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves.

Ramanath Majumdar1, Dylan V Miller, Karla V Ballman, Gopinathan Unnikrishnan, Stephen H McKellar, Gobinda Sarkar, Raghavakaimal Sreekumar, Mark E Bolander, Thoralf M Sundt.   

Abstract

OBJECTIVE: Ascending aortic aneurysms (AscAAs) are a highly lethal condition whose pathobiology remains to be poorly understood. Although most AscAAs occur in the presence of a trileaflet aortic valve (TAV), a bicuspid aortic valve (BAV) is a common congenital anomaly associated with an increased risk for an AscAA and dissection independent of functional valve pathology but secondary to inherent structural abnormality of the aorta. The objective of this investigation was to compare the patterns of gene expression in aortas between TAV and BAV patients with the aim of identifying markers for AscAAs.
METHODS: We used microarray analysis to first compare messenger RNA expressions between aneurysmal aortas from TAV patients (n=11) and those from BAV patients (n=11), identified genes overexpressed in TAV aneurysms, and compared expressions of the selected genes among TAV aneurysms, BAV aneurysms, and normal aortas (n=3). Finally, expressions of the selected genes were assessed by immunostaining of aortas from the TAV, BAV, and normal specimens.
RESULTS: Two overexpressed genes in the TAV group, osteopontin (OPN) and tenascin C (TNC), were consistently more highly expressed in TAV aneurysms than in BAV aneurysms and normal aortas as determined by real-time reverse transcriptase quantitative polymerase chain reaction and immunohistochemistry. Differential staining revealed that OPN protein was concentrated in the medial smooth muscle and that TNC protein was concentrated around the vasa vasorum.
CONCLUSIONS: We identified two novel potential markers, OPN and TNC, that are strongly associated with TAV aneurysms. The roles of OPN and TNC in influencing extracellular matrix remodeling in AscAAs warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502243     DOI: 10.1016/j.carpath.2006.12.001

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  12 in total

1.  Unraveling divergent gene expression profiles in bicuspid and tricuspid aortic valve patients with thoracic aortic dilatation: the ASAP study.

Authors:  Lasse Folkersen; Dick Wågsäter; Valentina Paloschi; Veronica Jackson; Johan Petrini; Sanela Kurtovic; Shohreh Maleki; Maria J Eriksson; Kenneth Caidahl; Anders Hamsten; Jean-Baptiste Michel; Jan Liska; Anders Gabrielsen; Anders Franco-Cereceda; Per Eriksson
Journal:  Mol Med       Date:  2011-09-27       Impact factor: 6.354

2.  Rare copy number variants disrupt genes regulating vascular smooth muscle cell adhesion and contractility in sporadic thoracic aortic aneurysms and dissections.

Authors:  Siddharth K Prakash; Scott A LeMaire; Dong-Chuan Guo; Ludivine Russell; Ellen S Regalado; Hossein Golabbakhsh; Ralph J Johnson; Hazim J Safi; Anthony L Estrera; Joseph S Coselli; Molly S Bray; Suzanne M Leal; Dianna M Milewicz; John W Belmont
Journal:  Am J Hum Genet       Date:  2010-11-18       Impact factor: 11.025

3.  Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall.

Authors:  Karola Trescher; Barbara Thometich; Svitlana Demyanets; Hermann Kassal; Roland Sedivy; Reginald Bittner; Christoph Holzinger; Bruno K Podesser
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-08

4.  miR-30e targets IGF2-regulated osteogenesis in bone marrow-derived mesenchymal stem cells, aortic smooth muscle cells, and ApoE-/- mice.

Authors:  Wen Ding; Jihe Li; Jayanti Singh; Razan Alif; Roberto I Vazquez-Padron; Samirah A Gomes; Joshua M Hare; Lina A Shehadeh
Journal:  Cardiovasc Res       Date:  2015-02-12       Impact factor: 10.787

5.  Application of gene network analysis techniques identifies AXIN1/PDIA2 and endoglin haplotypes associated with bicuspid aortic valve.

Authors:  Eric C Wooten; Lakshmanan K Iyer; Maria Claudia Montefusco; Alyson Kelley Hedgepeth; Douglas D Payne; Navin K Kapur; David E Housman; Michael E Mendelsohn; Gordon S Huggins
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

6.  Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.

Authors:  Jin-Hyung Lee; Atrayee Banerjee; Yoshi Ueno; Shashi K Ramaiah
Journal:  Toxicol Sci       Date:  2008-08-14       Impact factor: 4.849

7.  Differential expression of collagen type V and XI alpha-1 in human ascending thoracic aortic aneurysms.

Authors:  Ioannis K Toumpoulis; Julia Thom Oxford; Douglas B Cowan; Constantine E Anagnostopoulos; Chris K Rokkas; Themistocles P Chamogeorgakis; Dimitrios C Angouras; Richard J Shemin; Mohamad Navab; Maria Ericsson; Micheline Federman; Sidney Levitsky; James D McCully
Journal:  Ann Thorac Surg       Date:  2009-08       Impact factor: 4.330

Review 8.  Advances in tenascin-C biology.

Authors:  Kim S Midwood; Thomas Hussenet; Benoit Langlois; Gertraud Orend
Journal:  Cell Mol Life Sci       Date:  2011-08-05       Impact factor: 9.261

9.  The expression and role of tenascin C in abdominal aortic aneurysm formation and progression.

Authors:  Felix Nagel; Anne-Kristin Schaefer; Inês Fonseca Gonçalves; Eylem Acar; Andre Oszwald; Philipp Kaiser; Renate Kain; Karola Trescher; Wolf H Eilenberg; Christine Brostjan; David Santer; Attila Kiss; Bruno K Podesser
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-05-02

10.  Selection of reference genes for quantitative real time PCR (qPCR) assays in tissue from human ascending aorta.

Authors:  Carmen Rueda-Martínez; Oscar Lamas; María José Mataró; Juan Robledo-Carmona; Gemma Sánchez-Espín; Manuel Jiménez-Navarro; Miguel Such-Martínez; Borja Fernández
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.